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ASUMMARYSignaling by ErbB receptors requires the activationof their cytoplasmic kinase domains, which is initi-ated by ligand binding to the receptor ectodomains.Cytoplasmic factors contributing to the activationare unknown. Here we identify members of the cyto-
hesin protein family as such factors. Cytohesin inhi-
bition decreased ErbB receptor autophosphorylation
and signaling, whereas cytohesin overexpression
stimulated receptor activation. Monitoring epidermal
growth factor receptor (EGFR) conformation by
anisotropy microscopy together with cell-free recon-
stitution of cytohesin-dependent receptor autophos-
phorylation indicate that cytohesins facilitate confor-
mational rearrangements in the intracellular domains
of dimerized receptors. Consistent with cytohesins
playing a prominent role in ErbB receptor signaling,
we found that cytohesin overexpression correlated
with EGF signaling pathway activation in human
lung adenocarcinomas. Chemical inhibition of cyto-
hesins resulted in reduced proliferation of EGFR-
dependent lung cancer cells in vitro and in vivo.
Our results establish cytohesins as cytoplasmic
conformational activators of ErbB receptors that
are of pathophysiological relevance.
RE
TRINTRODUCTION
ErbB receptors are key regulators of cell differentiation, survival,
proliferation, and migration, and aberrant ErbB receptor functionis a hallmark of many human cancers (Fischer et al., 2003; Bublil
and Yarden, 2007). The ErbB receptor family is comprised of four
members, the epidermal growth factor receptor (EGFR/ErbB1),
Her2/ErbB2, Her3/ErbB3, and ErbB4. Signaling is initiated by
growth factor binding to the extracellular domains of the ErbB
receptors. The ligand-induced conformational change in the
receptor ectodomains results in the association of the cyto-
plasmic tyrosine kinase domains of two receptor molecules.
This association has been considered to be sufficient for
releasing the default autoinhibited state of the kinase domains
(Ferguson, 2008; Bose and Zhang, 2009). However, the picture
appears to be more complex as only a fraction of the dimerized
ErbB receptors are catalytically active (Gadella and Jovin, 1995;
Moriki et al., 2001; Cui et al., 2002), and because receptor dimer-
ization seems to occur continuously and reversibly even in the
absence of ligand (Chung et al., 2010). Recent crystallographic
studies indicate that catalytic activity may be restricted to dimers
that show a special arrangement of the kinase domains, the so-
called asymmetric dimers (Zhang et al., 2006; Qiu et al., 2008;
Jura et al., 2009; Red Brewer et al., 2009). However, determi-
nants defining the fraction of active dimers that form within the
entire population of dimerized receptors remain elusive. This
fraction may simply depend on the rate of the spontaneous
conversion from the symmetric to the asymmetric dimer. Alter-
natively, the fraction of active dimers may not simply be defined
by receptor-inherent properties alone or by an equilibrium
between the two receptor dimer populations but be modulated
by cytoplasmic activator proteins. Such activators would endow
the cell with the possibility to fine-tune the number of actively
signaling receptors within a given pool of ligand-occupied recep-
tors according to cellular needs. However, cytoplasmic activa-
tors of ErbB receptors have not yet been identified.
Here, we report cytohesins as cytoplasmic ErbB receptor acti-
vators. The cytohesin family consists of four highly homologous
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Figure 1. Cytohesins Enhance Activation of ErbB Receptors
(A and B) The cytohesin inhibitor SecinH3 reduces ErbB receptor signaling.
Western blot analysis of H460 (A) or SkBr3 (B) cells treated with SecinH3 or
solvent and stimulated with EGF or heregulin (HRG), respectively, is shown.
Phosphorylation of the indicated proteins was determined by immunodetec-
tion using phosphospecific antibodies. Heat shock cognate protein 70
(Hsc70) served as loading control. The diagrams show relative phosphoryla-
tion levels after normalization for Hsc70. The untreated ligand-stimulated cells
were set as 1 (n = 6).
(C and D) Overexpression of the cytohesin ARNO enhances ErbB receptor
autophosphorylation. H460 (C) or SkBr3 (D) cells were transfected with
increasing amounts of FLAG-tagged ARNO and stimulated with ligand.
Receptor autophosphorylation was analyzed as above (n = 3).
Data are represented as mean ± SEM. See Figure S1 for further information.
CT
EDmembers, including ubiquitously expressed cytohesin-1, cyto-
hesin-2 (ARNO), cytohesin-3 (Grp1), and cytohesin-4, which is
exclusively found in cells of the immune system (Kolanus,
2007). Cytohesins are guanine nucleotide exchange factors
(GEFs) for ADP ribosylation factors (ARFs) that belong to the
family of small Ras-like GTPases. As in the case of other small
GTPases, ARF function critically depends on activation by
GEFs (Bos et al., 2007). Thus, because ARFs are involved in con-
trolling cytoskeletal dynamics, cell migration, vesicular traffic,
and signaling (Casanova, 2007; Kolanus, 2007), cytohesins are
important regulators of these processes.
We show that cytohesins enhance EGFR activation by directly
interacting with the cytoplasmic domains of dimerized receptors
and by facilitating conformational rearrangements of these
domains. Chemical inhibition and knockdown of cytohesins
reduce EGFR activation, whereas cytohesin overexpression
has the opposite effect. Our results strongly suggest that EGF
and cytohesins concertedly determine the degree of EGFR acti-
vation. We propose that whereas EGF exhibits its known func-
tion from the extracellular side, namely to relieve the autoinhibi-
tion of the unliganded receptor, cytohesins function to adjust
EGFR signaling from the cytoplasmic side by increasing the
number of EGFR dimers having the active, catalytically compe-
tent conformation within the reservoir of ligand-bound EGFR
dimers. This model is further supported by the finding that cyto-
hesin expression levels in human tumors correlate with EGFR
activation and signaling and that the chemical inhibition of cyto-
hesins reduces cell proliferation in vitro and tumor growth in
mice. Thus, cytohesins are introduced as intracellular EGFR acti-
vators that are relevant in the pathophysiology of certain
cancers.
RESULTS
Chemical Inhibition and Knockdown of Cytohesins
Reduce ErbB Receptor Signaling
To test whether cytohesins are involved in ErbB receptor
signaling, we used the specific cytohesin antagonist SecinH3
(Hafner et al., 2006; Bi et al., 2008). For this purpose, EGFR-
expressing human lung adenocarcinoma-derived H460 cells
were stimulated with EGF in the presence of SecinH3. Using
autophosphorylation as a readout, we observed that SecinH3-
treated cells showed an about 50% inhibition of EGFR activation
(Figure 1A). The inhibitory effect was also found at the level of the
adaptor proteins IRS1 and Shc and of the downstream kinases
p44/42 (Erk1/Erk2). A control compound (XH1009) that is struc-
turally related to SecinH3 but does neither bind nor inhibit cyto-
hesins (Bi et al., 2008) had no effect on EGFR activation and
signaling (Figure S1A available online). To obtain SecinH3-inde-
pendent evidence, the cytohesin-specific aptamer M69 (Mayer
et al., 2001) or cytohesin-specific siRNAs were used. Inhibition
of EGFR activation was observed in both experiments (Figures
S1B and S1C). The re-expression of cytohesin-2/ARNO in
siRNA-treated cells rescued the effect of ARNO knockdown on
EGFR autophosphorylation (Figure S2A, lanes 4 and 6).
We then analyzed whether cytohesins also affected the
signaling of Her2 and Her3, two other members of the ErbB
receptor family forming a heterodimer. When Her2/Her3-ex-
RE
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A202 Cell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc.pressing human breast adenocarcinoma-derived SkBr3 cells
were treated with heregulin, SecinH3 reduced the phosphoryla-
tion of Her3 by about 50% (Figure 1B). This reduction in Her3
activation was mirrored in reduced activation of the adaptor
protein IRS1 and the downstream kinases Akt and p44/42.
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Figure 2. The Sec7 Domain Enhances the Autophosphorylation of
ErbB Receptors Independently of Its GEF Activity
(A and B) GEF-inactive ARNO enhances ErbB receptor autophosphorylation.
Shown is western blot analysis of protein lysates prepared from H460 (A) or
SkBr3 (B) cells transfectedwith FLAG-tagged wild-type ARNO or GEF-inactive
ARNO-E156K. Cells were stimulated with EGF or heregulin (HRG) and receptor
autophosphorylation was analyzed with phosphospecific antibodies.
(C) The Sec7 domain is sufficient for EGFR activation. H460 cells were trans-
fected with full-length ARNO (FL), with ARNO lacking the coiled-coil (DCC) or
the pleckstrin homology (DPH) domain, or with the isolated Sec7 domain
(Sec7). Autophosphorylation of the EGFR was determined as above.
See Figure S2 for further information.
CT
EDThe control compound XH1009 had no inhibitory effect (Fig-
ure S1D). Again, the involvement of cytohesins in the activation
of Her3 was confirmed by the aptamer M69 and by cytohesin-
specific siRNAs (Figures S1E and S1F).
Overexpression of ARNO Enhances EGFR Activation
Having shown that cytohesin inhibition and knockdown reduce
ErbB signaling, we asked whether overexpression of cytohesins
leads to an enhancement of EGF-stimulated EGFR activation.
For this analysis we have selected ARNO, which shows in both
H460 and SkBr3 cells higher expression than cytohesin-1 and
-3 (data not shown). When ARNO-transfected H460 cells were
stimulated with EGF, an ARNO-dependent increase in receptor
activation could be detected (Figure 1C). The same result was
seen in the Her2/Her3-expressing SkBr3 cells (Figure 1D). These
data show that ARNO, when overexpressed, enhances the
ligand-dependent activation of ErbB family members.
ARNO Enhances EGFR Activation Independently
of Its GEF Activity
The known function of ARNO is to act as a GEF on ARF proteins.
To analyze whether the GEF activity was also required for the
activation of the EGFR we made use of the GEF-inactive
ARNO mutant ARNO-E156K (Cherfils et al., 1998). Unexpect-
edly, overexpressed wild-type ARNO and ARNO-E156K were
equally potent in enhancing EGFR autophosphorylation (Fig-
ure 2A). The ability of ARNO-E156K to enhance EGFR activation
was not due to its overexpression as ARNO-E156K expressed at
endogenous protein level rescued the inhibition of EGFR auto-
phosphorylation induced by knockdown of endogenous ARNO
(Figure S2A, lanes 5 and 7). The mutant also stimulated Her2/
Her3 autophosphorylation (Figure 2B), suggesting that the GEF
activity is not required for the ARNO-mediated activation of
ErbB receptors. To substantiate this observation, we reduced
the expression of ARF1 or ARF6 by RNA interference. Neither
the knockdown of ARF1 nor that of ARF6 had an influence
on the activation of the EGFR (Figure S2B) or Her2/Her3 (Fig-
ure S2C). These results indicate that the cytohesin-mediated
activation of ErbB receptors does not involve these ARF
proteins, nor does it require the GEF function of the Sec7
domain, and thus implicate a hitherto unknown GEF-indepen-
dent function of ARNO.
As SecinH3 targets the Sec7 domain of the cytohesins (Hafner
et al., 2006; Bi et al., 2008), we asked whether this domain was
sufficient for EGFR activation or whether cytohesins’ pleck-
strin-homology (PH) and/or coiled-coil (CC) domains were also
required (Lim et al., 2010). Deletion studies showed that ARNO’s
Sec7 domain stimulated EGFR autophosphorylation as well as
the full-length protein (Figure 2C), attributing the EGFR-acti-
vating capability of the cytohesins to this domain.
ARNO Acts on Dimerized Receptors
Depending on determinants that are as yet incompletely under-
stood, ErbB receptor activation by growth factor ligands may
(Nagy et al., 1999) or may not (Abulrob et al., 2010) be accompa-
nied by receptor clustering. As the enhancement of EGFR activa-
tion by cytohesins could be due to an effect of cytohesins on
EGFR clustering, we examined by superresolution light micros-
RE
TR copy (Hell and Wichmann, 1994) whether ARNO was involvedin the EGF-dependent EGFR clustering. We found a slight
increase in the measured EGFR cluster size upon EGF stimula-
tion, which was not affected by SecinH3 (Figure 3A and Figures
S3B and S3C), indicating that the reduction of EGFR signaling
observed after cytohesin inhibition is not a result of alterations
in cluster size at the observed 100 nm scale.
Cytohesins are involved in endocytosis (D’Souza-Schorey
and Chavrier, 2006) and thus could augment EGFR activa-
tion indirectly by modulating the endocytosis or degradation
of the EGFR. However, quantification of the EGFR at the
plasma membrane after EGF stimulation revealed no differ-
ence between untreated and SecinH3-treated cells, arguing
against this assumption (Figure 3B and Figure S3A). Generally,
EGFR activation by EGF enhances receptor endocytosis
(Sorkin and Goh, 2008) and thus might lead to the assumption
that the reduced EGFR activation after cytohesin inhibition
would slow down EGFR endocytosis. However, recently, it was
shown that receptor dimerization and not receptor activity is
a prerequisite for endocytosis (Wang et al., 2005). Therefore,
our finding that SecinH3 treatment does not reduce receptorCell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc. 203
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Figure 3. Cytohesins Enhance the Phosphorylation but Not the
Dimerization of EGFR
(A) Cytohesins do not alter EGFR cluster size at the observed 100 nm scale.
SecinH3-treated or untreated H460 cells were stimulated with EGF, and EGFR
cluster sizes were determined by STED microscopy on plasma membrane
sheets. Each condition in each experiment (n = 3) includes 105–480 clusters
measured from 10–12 membrane sheets. *p < 0.05.
(B) SecinH3 does not affect EGF-triggered internalization of EGFR. SecinH3-
treated or untreated H460 cells were stimulated with EGF and the EGFR
remaining at the plasma membrane was quantified on plasma membrane
sheets by immunofluorescencemicroscopy. Statistical evaluation was of three
independent experiments each comprising the analysis of 26–66 membrane
sheets per condition.
(C–F) Cytohesins enhance phosphorylation of ErbB dimers. H460 (C and D) or
SkBr3 (E and F) cells were either treated with SecinH3 (C and E) or transfected
with ARNO (D and F), stimulated with ligand for 5 min and chemically cross-
linked. Receptor phosphorylation was analyzed by phosphospecific anti-
bodies. Arrows indicate receptor dimers. Diagrams show the phosphorylation
of the crosslinked, i.e., dimeric, receptors only after normalization for total
dimeric receptor (n = 9 for SecinH3 treatment, n = 5 for ARNO overexpression).
Data are represented as mean ± SEM. See Figure S3 for further information.
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TR
Ainternalization suggests that EGFR dimerization does not
depend on cytohesins.
To analyze the effect of cytohesins on receptor dimerization
more directly, H460 cells were preincubated with SecinH3, stim-204 Cell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc.ulated, and treated with crosslinker to trap dimeric receptors.
Cytohesin inhibition did not affect receptor dimerization but
reduced the phosphorylation of the dimerized receptors (Fig-
ure 3C). Consistently, ARNO overexpression led to increased
phosphorylation of EGFR dimers, whereas it had no effect
on receptor dimerization (Figure 3D). The same results were
obtained for Her2/Her3 receptors in SkBr3 cells (Figures 3E
and 3F). These data suggest that ARNO facilitates the activation
of already dimerized ErbB receptors.
To obtain further evidence for this assumption, we analyzed
directly whether ARNO acts on dimeric receptors. A constitu-
tively dimerized EGFR (lz-EGFR; Figure 4A) was constructed
by replacing the extracellular domain of the receptor with a
dimerization module consisting of a leucine zipper and a single
cysteine residue that forms a disulfide bridge upon dimeriza-
tion (Stuhlmann-Laeisz et al., 2006). When the lz-EGFR was
expressed in HEK293 cells it was found exclusively as a dimer
(Figure S4A, upper panel). Consistent with its constitutive dimer-
ization, lz-EGFR was phosphorylated (Figure S4A, lower panel).
To test whether the activation of the lz-EGFR kinase domain
was dependent on the formation of the asymmetric dimer, the
effect of MIG6 on the autophosphorylation of the lz-EGFR was
analyzed. MIG6 inhibits receptor autophosphorylation by pre-
venting the formation of the active asymmetric EGFR dimer
(Zhang et al., 2007). Coexpression of the EGFR-binding domain
of MIG6 (MIG6-EBR), which is sufficient to inhibit EGFR signaling
(Anastasi et al., 2007), reduced lz-EGFR receptor autophosphor-
ylation, suggesting that the activation of the lz-EGFR depends
on the formation of the asymmetric dimer (Figure S4B). Thus,
regarding the allosteric activation of the kinase domains, the
lz-EGFR appears to behave like an authentic EGFR. Therefore,
the lz-EGFR is a suitable model to ask whether ARNO enhances
the activation of the EGFR kinase after its dimerization.
To address this question, ARNO activity was modulated in
lz-EGFR-expressing cells. In the presence of SecinH3, the auto-
phosphorylation of lz-EGFR was reduced (Figure 4B). The
control compound XH1009 had no effect (Figure S4C). Consis-
tently, overexpression of ARNO in these cells led to an increased
autophosphorylation of lz-EGFR (Figure 4C). These data pro-
vide strong evidence for the hypothesis that ARNO enhances
the activation of already dimerized EGFR, possibly by facilitating
conformational rearrangements.
CT
EDARNO Facilitates a Conformational Rearrangement
of the Cytoplasmic Domains of the Dimerized EGFR
To visualize conformational changes of the EGFR cytoplasmic
domains in living cells we tagged each molecule in the dimeric
lz-EGFR at the C terminus with the fluorescent protein mCitrine
(lz-EGFR-mCitrine). Like the untagged lz-EGFR, the fusion pro-
tein was constitutively dimerized and autophosphorylated (Fig-
ure S4D) and reached the plasma membrane, as visualized by
fluorescence microscopy on plasma membrane sheets (data
not shown), demonstrating that the mCitrine did not perturb
receptor function. Changes in the positions of the two mCitrine
moieties relative to each other result in changes in the fluores-
cence resonance energy transfer between these proteins (homo-
FRET). The efficiency of homo-FRET, which is exquisitely
CD
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Figure 4. Cytohesins Facilitate a Conforma-
tional Rearrangement of the Intracellular
Domains of EGFR Dimers
(A) Schematic of the constitutively dimerized lz-
EGFR. The extracellular domain of EGFR was re-
placed by a Flag-tagged disulfide-bridged leucine
zipper dimerization module.
(B and C) ARNO enhances the autophosphorlya-
tion of lz-EGFR. Shown are western blot analyses
of HEK293 cells transfected with lz-EGFR and
treated with SecinH3 (B) or cotransfected with
ARNO (C). The phosphorylation of lz-EGFR was
analyzed by phosphospecific antibodies (p-lz-
EGFR). Diagrams show receptor phosphorylation
after normalization for total receptor (n = 5). The
double bands in the FLAG blots correspond to un-
phosphorylated (lower) and phosphorylated
(upper) lz-EGFR.
(D) ARNO facilitates a conformational rearrange-
ment of the intracellular domains of constitutively
dimerized EGFR. For fluorescence anisotropy
microscopy, the C termini of both EGFRmolecules
in lz-EGFR were tagged with mCitrine (lz-EGFR-
mCitrine). COS-7 cells were cotransfected with
lz-EGFR-mCitrine and empty vector (left) or
together with increasing amounts of ARNO
(middle and right). Homo-FRET between the two
mCitrinemoieties was determined by steady-state
fluorescence anisotropymicroscopy. The diagram
shows the statistic evaluation of five experiments,
each covering 25 fields of view with 1–4 cells.
Data are represented as mean ± SEM. See
Figure S4 for further information.AC
T
Dsensitive to both the distance and the orientation of the fluoro-
phores, can be determined by measuring the steady-state fluo-
rescence anisotropy of the cells (Squire et al., 2004). This tech-
nique has recently been used to monitor conformational
changes in the neurotrophin receptor (Vilar et al., 2009). To test
whether it is also suited to detect conformational changes in
the EGFR cytoplasmic domains, we expressed lz-EGFR-
mCitrine in COS-7 cells either alone, together with MIG6, or
together with Rheb. Whereas MIG6 is expected to change the
steady-state fluorescence anisotropy of lz-EGFR-mCitrine,
Rheb, which is not involved in EGFR signaling, should have no
effect. As expected, coexpression of MIG6-EBR led to a change
in the steady-state fluorescence anisotropy of lz-EGFR-mCitrine
whereas coexpression of Rheb did not (Figure S4E). Thus,
anisotropy measurements are suited to detect differences in
lz-EGFR-mCitrine conformation. To detect ARNO-dependent
conformational changes in the EGFR cytoplasmic domains,
lz-EGFR-mCitrine was expressed together with ARNO. The co-
expression of ARNO led to a decrease in anisotropy as com-
pared to lz-EGFR-mCitrine alone (Figure 4D). As ARNO neither
changed the fluorescence anisotropy of lz-mCitrine (which
does not contain the EGFR cytoplasmic domain) nor the fluores-
cence lifetime of lz-EGFR-mCitrine (data not shown), these
results indicate that ARNO coexpression resulted in an altered
conformation of the cytoplasmic domains of the EGFR dimer.
Although the geometries of the EGFR dimers in the EGFR-
ARNO and EGFR-MIG6 complexes are expected to be different,
R
TRwe found in both cases a decrease in fluorescence anisotropy.
At first view, these results seem mutually contradictory as it
might intuitively be anticipated that changes in anisotropy
produced by an inhibitor would oppose those of an activator.
It should be noted, however, that anisotropy depends on both
the distance and the relative orientation of the fluorophores.
Therefore, even if the anisotropy is equal in two situations the
underlying geometry can be quite different. Although a specific
conformation thus cannot be deduced from a certain value of
anisotropy, a change in anisotropy is a reliable indicator for
a change in geometry (Vilar et al., 2009). Together with the anal-
ysis of receptor crosslinking and phosphorylation, these results
support the hypothesis that ARNO enhances receptor activation
by facilitating a conformational rearrangement of the cyto-
plasmic domains of the dimerized EGFR.Cell-free Reconstitution of ARNO-Dependent EGFR
Activation
ARNO’s function as a conformational activator of the EGFR
implies ARNO and the EGFR to physically interact. Immunoflu-
orescence microscopy of plasma membrane sheets showed
that ARNO and the EGFR colocalize in H460 cells (Fig-
ure 5A). Moreover, coimmunoprecipitation of ARNO and the
EGFR indicated complex formation between the two pro-
teins (Figure 5B). To gain evidence for direct interaction of
ARNO and the cytoplasmic domain of the EGFR, a cell-freeCell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc. 205
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A Figure 5. ARNO Stimulates Autophosphor-
ylation of EGFR by Direct Interaction
(A) ARNO colocalizes with EGFR. Plasma mem-
brane sheets were immunostained for EGFR
(red channel, left panels) and ARNO/cytohesin-1
(green channel, middle panels). Right panels
show corresponding overlays. To quantify coloc-
alization, circles were superimposed concen-
trically on selected spots in the red channel
and transferred to identical pixel locations in
the green channel. Continuous and dashed
circles indicate positive and negative colocaliza-
tion signals, respectively. 62% ± 5% of
the EGFR spots were positive for ARNO
(n = 3).
(B) Coimmunoprecipitation of ARNO with EGFR.
EGFR was immunoprecipitated from H460 cells
with agarose-coupled anti-EGFR. Coprecipitated
ARNO was detected by an ARNO-specific anti-
body. Agarose-coupled normal mouse IgG was
used as control matrix.
(C) ARNO interacts with the intracellular domain
of the EGFR (EGFR-ICD) in vitro. The indicated
protein was labeled with FITC and the unlabeled
ligand was added at increasing concentrations.
Binding was measured by fluorescence anisot-
ropy. KD values were calculated assuming a 1:1
stoichiometry (n=4) and are given as mean ±
SEM. n.b., no binding.
(D) ARNO enhances autophosphorylation of
EGFR-ICD. The indicated ARNO construct and
EGFR-ICD were incubated in vitro. Autophos-
phorylation was initiated by addition of ATP.
Samples were taken at the indicated time points
and analyzed using antiphosphotyrosine antibody
(pY). EGFR-ICD and ARNO constructs were
detected with anti-His-antibody.
See Figure S5 for further information.
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Dreconstitution system was used. The complete cytoplasmic
domain of the EGFR (EGFR-ICD) and ARNO were heterolo-
gously expressed (Figures S5A and S5B), and the interac-
tion of the purified, FITC-labeled proteins was analyzed by fluo-
rescence anisotropy measurements (Figure 5C). Full-length
ARNO, the isolated Sec7 domain, and the GEF-inactive Sec7-
E156K bound to the EGFR-ICD with apparent dissociation
constants around 1 mM. Segment 1 of MIG6-EBR (MIG6-S1),
a known binding partner of the EGFR-ICD (Zhang et al.,
2007), bound with a dissociation constant (KD) around 2 mM.
No binding was observed between lysozyme and EGFR-ICD,
nor did ARNO full-length or ARNO-Sec7 show binding to
MIG6-S1 (Figure 5C), indicating that the observed binding is
specific. EGFR-ICD lacking the C-terminal 188 amino acids
(EGFR-ICD1022) bound to ARNO-Sec7 with the same affinity
as the complete EGFR-ICD confining ARNO’s binding site
to the kinase or juxtamembrane domains of the EGFR.
In agreement with ARNO functioning upstream of EGFR auto-
R
206 Cell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc.phosphorylation, the binding of ARNO did not require phos-
phorylation of the EGFR-ICD (Figure S5C).
Due to the presence of the juxtamembrane segment, EGFR-
ICD forms a dimer resembling the intracellular domains of the
ligand-bound EGFR (Jura et al., 2009) and thus can be used
to analyze the autophosphorylation of the EGFR in a cell-free
system. To test whether the conformational requirements for
the activation of the authentic EGFR are preserved in EGFR-
ICD, an autophosphorylation reaction of EGFR-ICD was per-
formed in the presence of MIG6-S1, which inhibits the forma-
tion of the asymmetric dimer of the EGFR (Zhang et al.,
2007). MIG6-S1 reduced the autophosphorylation of EGFR-
ICD (Figure S5D), indicating that the activation of the EGFR-
ICD kinase depends on the formation of the asymmetric dimer.
Addition of GST had no effect (Figure S5D). When ARNO was
added to an autophosphorylation reaction of EGFR-ICD,
increased autophosphorylation was found (Figure 5D). A similar
level of stimulation was seen when the isolated Sec7 domain
pEGFR
pp42/pp44
ARNO/
cytohesin-1 
pAkt
A
B
C
D
0
20
40
60
80
100]%[ latot fo noitcarf 1 2 30
cytohesin score
strong
moderate
weak
background
staining
0
20
40
60
80
100]%[ latot fo noitcarf 1 2 30
cytohesin score
0
20
40
60
80
100]%[ latot fo noitcarf 1 2 30
cytohesin score
cytohesin score 
frequencies [%] 
53
2
29
16 stainingscore
3   strong
2   moderate
1   weak
0   background
cytohesin score
0 3
Figure 6. High Expression Levels of ARNO/
Cytohesin-1 Correlate with Increased EGFR
Signaling in Human Lung Adenocarcinomas
Consecutive sections of resected human lung
adenocarcinomas were stained for ARNO/cytohe-
sin-1 (A), pEGFR (B), pAkt (C), pp44/42 (D). Repre-
sentative images of tumors with background (left
column) or strong (right column) ARNO/cytohe-
sin-1 expression are shown. The diagram in (A)
shows the fraction of tumors with background
(score 0), weak (score 1), moderate (score 2), or
strong (score 3) staining for ARNO/cytohesin-1.
The diagrams in (B)–(D) depict the phosphorylation
levels of the respective protein in correlation to the
cytohesin score (p = 0.002 for pEGFR, p = 0.002
for pAkt, p = 0.025 for pp44/42, n = 45).
See Figure S6 for further information.
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C
Dor Sec7-E156K was added. Taken together with the data
obtained in the cellular assays, these results strongly argue
for cytohesins acting on the intracellular domains of dimerized
EGFR as conformational activators.
TE
Cytohesin Overexpression Correlates with Enhanced
EGFR Signaling in Human Lung Cancers
Enhanced EGFR signaling is known to be a hallmark in many
cancers. Having shown that ARNO enhances EGFR activation
in H460 cells, we wondered whether ARNO or other cytohesins
might be overexpressed in lung cancer. To address this ques-
tion, we immunostained primary human lung adenocarcinomas
with an antibody detecting ARNO and cytohesin-1. Whereas
normal lung tissue showed only background or weak staining,
82% of the carcinomas showed moderate or strong ARNO/
cytohesin-1 staining (Figure 6A), demonstrating cytohesin upre-
gulation in a large fraction of lung adenocarcinomas. According
to our in vitro data, increased cytohesin expression should
result in enhanced EGFR autophosphorylation in these tumors.Cell 143, 201–211,Indeed, we found a highly significant
(p = 0.002) correlation between the
expression level of ARNO/cytohesin-1
and the level of EGFR autophosphoryla-
tion (Figure 6B) in consecutive sections
of tumor tissue. Immunofluorescence
double-staining of phosphorylated EGFR
and ARNO further supported this correla-
tion (Figure S6). The increased EGFR
phosphorylation was not due to overex-
pression of the receptor because total
EGFR expression was independent of
the ARNO/cytohesin-1 expression (p =
0.581). The phosphorylation of Akt (Fig-
ure 6C) and p44/42 (Erk1/Erk2) (Fig-
ure 6D) was also significantly correlated
with higher ARNO/cytohesin-1 expres-
sion (p = 0.002 and p = 0.025, respec-
tively), suggesting that the enhanced acti-
vation is not restricted to the EGFR itself
TEbut continues along these two major branches of the EGF
signaling pathway.SecinH3 Reduces Growth of EGFR-Dependent Lung
Tumor Xenografts
The strong expression of ARNO/cytohesin-1 in tumor tissue
raised the question of whether cytohesins may, by enhanced
EGFR signaling, promote the proliferation of the tumor cells. To
test this possibility, the proliferation rate of the EGFR-dependent
lung cancer cell line PC9 was determined in the presence or
absence of SecinH3. Indeed, the inhibition of cytohesins led to
a strong reduction of the proliferation of PC9 cells (Figure 7A).
Because the inhibition of EGFR signaling in EGFR-dependent
cells results in cell-cycle arrest and the induction of apoptosis
(Sharma et al., 2007), we examined SecinH3-treated PC9 cells
for cell-cycle arrest and apoptosis. We found an increase of cells
in the G1 phase of the cell cycle and a concomitant decrease of
cells in S and G2/M phases, indicative of SecinH3 inducing an
arrest in G1 of the cell cycle (Figure 7B). Accordingly, AnnexinOctober 15, 2010 ª2010 Elsevier Inc. 207
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Figure 7. SecinH3 Inhibits Growth of EGFR-
Dependent Lung Tumor Xenografts
(A) SecinH3 inhibits proliferation of PC9 cells. The
diagram shows the relative cell number (MTT
assay) after 72 hr treatment with SecinH3 or
DMSO. The cell number in the solvent-treated
samples was set to 1. ***p < 0.001, n = 9.
(B) SecinH3 induces G1 arrest in PC9 cells. PC9
cells were treated with SecinH3 or solvent for
24 hr, fixed, stained with TOPRO-3, and analyzed
by flow cytometry. The diagram shows the
percentage of cells in the indicated cell-cycle
phases. ***p < 0.001, n = 6.
(C) SecinH3 induces apoptosis in PC9 cells.
Annexin V FACS was performed after 48 hr treat-
ment with SecinH3 or solvent. The diagram shows
the percentage of apoptotic cells. ***p < 0.001,
n = 3.
(D) [18F]FLT PET indicates response to SecinH3.
Representative [18F]FLT PET images of mice
bearing PC9 xenografts before and 7 days after
treatment with SecinH3 or carrier (DMSO). **p <
0.01, n = 7.
(E) SecinH3 decreases proliferation of PC9 xeno-
grafts. Ki-67 staining of PC9 xenograft tumors in
nude mice after treatment with carrier or SecinH3
for 7 days.
(F) SecinH3 induces apoptosis in PC9 xenografts.
TUNEL assay of PC9 xenograft tumors in nude
mice after treatment with carrier or SecinH3 for
7 days. The diagram shows the number of TUNEL-
positive cells per high power microscopic field.
Per treatment group, 10 representative fields
were counted. ***p < 0.001.
Data are represented as mean ± SEM.
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EDV staining showed that SecinH3 treatment led to an increase of
apoptotic cells (Figure 7C). To test whether SecinH3 treatment
reduced tumor growth in vivo, tumor xenografts were generated
by subcutaneous injection of PC9 cells into nude mice. Cell
proliferation in the tumors was followed by [18F]-fluoro-L-thymi-
dine uptake positron emission tomography ([18F]FLT PET)
(Shields et al., 1998). The tumors in the SecinH3-treated mice
showed significantly less uptake of [18F]FLT (Figure 7D), indi-
cating reduced tumor growth. Further, immunohistochemical
staining of the cell proliferation marker Ki-67 (Gerdes et al.,
1983) in resected tumors confirmed reduced cell proliferation
(Figure 7E), and TUNEL staining showed an increase in apoptotic
cells in the tumors of SecinH3-treated animals (Figure 7F). Taken
together, these data demonstrate that the chemical inhibition of
R
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acytohesins reduces the proliferation of
EGFR-dependent tumor cells in vitro
and in vivo.
DISCUSSION
In the present study, we identify cytohe-
sins as ErbB receptor activators that
enhance receptor activation by direct
interaction with the cytoplasmic domainf the receptor. The importance of this kind of ErbB receptor
ctivator is underlined by the findings that increased cytohesin
xpression correlates with increased EGFR activation and sig-
aling in human lung cancers, and that the chemical inhibition
f cytohesins reduces the proliferation of EGFR-dependent
ng cancer cells in vitro and in mice. Except for Dok-7, cyto-
lasmic activators have not been described for any receptor
rosine kinase. Dok-7 enhances the activity of the muscle-
pecific receptor kinase MuSK by dimerizing partially autophos-
horylated and thus partially activated receptor monomers
noue et al., 2009; Bergamin et al., 2010). In contrast, cytohesins
o neither influence receptor dimerization nor require receptor
utophosphorylation for binding but function as conformational
ctivators of receptor dimers.
AFrom crystallographic, biochemical, and biophysical data it is
becoming increasingly evident that EGFR dimerization and acti-
vation of the kinase domains are distinctly regulated and thor-
oughly balanced processes, but the mechanisms by which this
balance is achieved are largely elusive. The fundamental model
of EGFR activation held that the activation of the EGFR kinase
results from the EGF-dependent dimerization of the receptor
cytoplasmic domains (Yarden and Schlessinger, 1987). This
model had to be extended when it was shown that the mere
dimerization of the EGFR is not sufficient for activation (Gadella
and Jovin, 1995; Moriki et al., 2001; Cui et al., 2002; Chung et al.,
2010). Recent crystallographic studies strongly suggest that
only a subset of the dimers that adopt a distinct conformation
called the asymmetric dimers, where one kinase acts as an allo-
steric activator for the other, are catalytically active (Zhang et al.,
2006; Jura et al., 2009; Red Brewer et al., 2009). Integration of
these data into the prior model led to the currently prevailing
model of EGFR activation according to which the activation of
the EGFR kinase results from the intrinsic ability of the receptor
kinase domains to form active (asymmetric) dimers as soon as
they are released from their default autoinhibited state (Fergu-
son, 2008; Bose and Zhang, 2009). The only activator required
in this model is the ligand EGF, which binds to the ectodomain
of the receptor and thereby induces and/or stabilizes the
structural rearrangements that release the kinase domains
from their autoinhibited state. Our finding that EGFR activation
is enhanced by cytohesins both in cells and in a cell-free recon-
stitution system indicates that EGFR activation is likely not
comprehensively explained by ligand-induced release from
autoinhibition and the subsequent spontaneaus formation of
the asymmetric dimer. The existence of cytoplasmic EGFR acti-
vators like cytohesins does not preclude receptor activation to
occur in their absence as seen for EGFR-ICD in our cell-free au-
tophosphorylation experiments and as seen for near-full length
EGFR in experiments by others (Mi et al., 2008; Qiu et al.,
2009). Our results implicate, however, a further extension of
the current model of EGFR activation to include additional layers
of regulation.
Indeed, in a cellular context, the transition from the inactive
symmetric to the active asymmetric dimer represents a stage
where additional layers of modulation of receptor activation,
inhibitory as well as stimulatory, might come into play. Recently,
MIG6 was identified as an inhibitor of EGFR signaling (Ferby
et al., 2006; Anastasi et al., 2007; Reschke et al., 2009) that
acts by blocking the formation of the asymmetric dimer (Zhang
et al., 2007), indicating that a layer of negative regulation appears
actually implemented. Cytohesins represent an example of
a class of EGFR activators that may form a layer of positive regu-
lation by facilitating the structural rearrangements required to
convert the receptor dimer into its active conformation. It is
important to point out that the existence of cytoplasmic EGFR
activators does not abolish ligand dependency of receptor acti-
vation because the autoinhibition that is imposed by the extra-
cellular domains on the kinase domain (Zhu et al., 2003) still
has to be released by ligand binding. Such activators do,
however, allow the cell to modulate, for a given amount of
ligand-bound receptor, the number of activated receptors
according to cellular needs.
ET
ROn the other hand, dysregulation of cytoplasmic EGFR activa-
tors like the cytohesin ARNO might result in inappropriately
activated EGFR signaling. Enhanced EGFR signaling is a charac-
teristic feature of several cancers including non-small cell
lung cancers (Gazdar, 2009). Cancer cells that critically depend
on a specific signaling molecule for growth and survival are
addicted to that oncogene (Weinstein, 2002), and those lung
cancers that respond to EGFR tyrosine kinase inhibitor therapy
are addicted to EGFR (Sharma et al., 2007). Themajority of these
tumors have either upregulated or mutant EGFR (Lynch et al.,
2004; Paez et al., 2004; Pao et al., 2004). Nevertheless, a signif-
icant fraction of lung cancers with apparently normal EGFR
status also respond to EGFR inhibitors, reflecting their EGFR
addiction (Sharma and Settleman, 2009). How these tumor cells
maintain a sufficient level of EGFR signaling to satisfy their EGFR
addiction is currently unclear. Our observation that ARNO over-
expression is associated with an activated EGF signaling path-
way in human lung adenocarcinoma provides a possible expla-
nation for the EGFR addiction of these cancer cells that have
neither mutant nor overexpressed EGFR. Our finding that
the proliferation of EGFR-dependent tumor cells is drastically
reduced by inhibition of cytohesins underlines the pathophysio-
logical significance of intracellular ErbB receptor activators like
ARNO and opens up avenues for fighting ErbB receptor-depen-
dent cancers by targeting not the receptors themselves but their
activators.CT
EDEXPERIMENTAL PROCEDURES
For detailed protocols allowing reproduction of the experiments, see Extended
Experimental Procedures.
Immunoblotting/Immunoprecipitation
Cells were serum-starved overnight in the presence of SecinH3 or DMSO and
stimulated for 5 min with EGF or heregulin-b1. Proteins were first immunopre-
cipitated or directly analyzed by SDS-PAGE and immunoblotting. Visualization
was done by enhanced chemiluminescence or by fluorescence-labeled
secondary antibodies.
Crosslinking
Cells were starved overnight in the presence of SecinH3 or DMSO. Directly
after stimulation (5 min), proteins were crosslinked by adding BS3 and
analyzed by SDS-PAGE and immunoblotting.
Anisotropy Microscopy
Anisotropy microscopy was done as described (Squire et al., 2004) in COS-7
cells.
STED Microsocopy and Immunofluorescence Microscopy
Membrane sheets were generated essentially as previously described (Lang
et al., 2001) and visualized either by epi-fluorescence or stimulated emission
depletion (STED) microscopy.
Cell-free Fluorescence Anisotropy and Autophosphorylation Assays
Fluorescein-labeled ARNO, ARNO-Sec7-WT/E156K, MIG6-EBR, or lysozyme
was mixed with unlabeled EGFR-ICD or MIG6-EBR at room temperature, and
fluorescence anisotropy was measured in a microplate reader. For the auto-
phosphorylation assays, EGFR-ICD was incubated with the indicated protein
in the presence of ATP at room temperature. After the indicated time, aliquots
were removed, separated by SDS-PAGE, and analyzed by immunoblotting.Cell 143, 201–211, October 15, 2010 ª2010 Elsevier Inc. 209
Tumor Samples
All tumor samples stem from the CIO Biobank at the Institute of Pathology,
University of Bonn, Germany. All tumors were clinically and pathologically
identified as being the primary and only neoplastic lesion and classified
according to World Health Organization (WHO) guidelines (Brambilla et al.,
2001). Sections were stained and evaluated as previously described (Heu-
kamp et al., 2006; Zimmer et al., 2008). Staining intensities were individually
evaluated by three independent observers using a four-tier scoring system
as described before (Zimmer et al., 2008). Immunofluorescence double-stain-
ing of tumor sections was performed as described (Friedrichs et al., 2007).
Proliferation and Apoptosis Assays
PC9 cells were treated with SecinH3 or solvent in medium containing 1% FCS.
Proliferation was analyzed after 3 days using aMTT assay. Apoptosis and cell-
cycle status were determined after 2 days by Annexin V and TOPRO-3 staining
and fluorescence-activated cell sorting (FACS) analysis.
[18F]FLT PET Imaging of Tumor Xenografts
nu/nu athymic mice that had been subcutaneously injected with PC9 cells
were treated with SecinH3 or DMSO for 7 days. After [18F]FLT (30-deoxy-30-
[F-18]fluorothymidine) administration tumors were visualized using a FOCUS
microPET scanner.
Statistics
Results are given as the mean ± standard error of the mean (SEM). Statistical
analyses were performed with Prism (GraphPad Software) applying the two-
tailed t test or one-way ANOVA, as appropriate. All datasets passed the
Kolmogorov and Smirnov test for Gaussian distribution. For the analysis of
the tumor samples the Spearman nonparametric correlation test was used.
Differences of means were considered significant at a significance level
of 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2010.09.011.
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